{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:52:21Z","timestamp":1790949141515,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.prro.2021.03.005","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T08:36:40Z","timestamp":1625128600000},"page":"e355-e365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Organ at Risk Dose Constraints in SABR: A Systematic Review of Active Clinical Trials"],"prefix":"10.1016","volume":"11","author":[{"given":"Serenna G.","family":"Gerhard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9542-0627","authenticated-orcid":false,"given":"David A.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Arifin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Al-Shafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George B.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol W.","family":"Bassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Corkum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2021.03.005_bib0001","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.21037\/cco.2017.06.20","article-title":"Stereotactic radiotherapy in oligometastatic cancer","volume":"6","author":"Kennedy","year":"2017","journal-title":"Chinese Clin Oncol"},{"key":"10.1016\/j.prro.2021.03.005_bib0002","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.03.005_bib0003","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2021.03.005_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2021.03.005_bib0005","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.03.005_bib0006","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.03.005_bib0007","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ijrobp.2019.08.031","article-title":"Primary outcomes of a phase II randomized trial of Observation versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE)","volume":"105","author":"Phillips","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.prro.2021.03.005_bib0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 SUPPL.","key":"10.1016\/j.prro.2021.03.005_bib0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.03.005_bib0010","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijrobp.2019.09.038","article-title":"Spinal cord dose tolerance to stereotactic body radiation therapy","volume":"110","author":"Sahgal","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.03.005_bib0011","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijrobp.2017.12.290","article-title":"Radiation dose-volume effects for liver SBRT","volume":"110","author":"Miften","year":"2021","journal-title":"Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.03.005_bib0012","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijrobp.2018.11.028","article-title":"Organs at risk considerations for thoracic stereotactic body radiation therapy: What is safe for lung parenchyma?","volume":"110","author":"Kong(Spring)","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.03.005_bib0013","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijrobp.2018.01.044","article-title":"Head and neck tumor control probability: Radiation dose-volume effects in stereotactic body radiation therapy for locally recurrent previously-irradiated head and neck cancer: Report of the AAPM Working Group","volume":"110","author":"Vargo","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.03.005_bib0014","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijrobp.2018.01.053","article-title":"Single- and multi-fraction stereotactic radiosurgery dose tolerances of the optic pathways","volume":"110","author":"Milano","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.03.005_bib0015","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: The report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.prro.2021.03.005_bib0016","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","article-title":"An overview of hypofractionation and introduction to this issue of seminars in radiation oncology","volume":"18","author":"Timmerman","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.prro.2021.03.005_bib0017","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.semradonc.2017.04.007","article-title":"Emphasis on repair, not just avoidance of injury, facilitates prudent stereotactic ablative radiotherapy","volume":"27","author":"Kim","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.prro.2021.03.005_bib0018","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK consensus on normal tissue dose constraints for stereotactic radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.prro.2021.03.005_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-018-1001-6","article-title":"Stereotactic ablative radiotherapy for ultra-central lung tumors: Prioritize target coverage or organs at risk?","volume":"13","author":"Murrell","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2021.03.005_bib0020","first-page":"34","article-title":"A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions","volume":"9","author":"Li","year":"2020","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.prro.2021.03.005_bib0021","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3389\/fonc.2019.00543","article-title":"A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: Where will the evidence lead?","volume":"9","author":"Al-Shafa","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2021.03.005_bib0022","unstructured":"NRG Oncology. A phase 1 study of stereotactic body radiotherapy (SBRT) for the treatment of multiple metastases. Available at: https:\/\/www.rtog.org\/ClinicalTrials\/ProtocolTable\/StudyDetails.aspx?action=openFile&FileID=11271. Accessed March 22, 2021."},{"key":"10.1016\/j.prro.2021.03.005_bib0023","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","article-title":"Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review","volume":"53","author":"Kroeze","year":"2017","journal-title":"Cancer Treat Rev"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850021001053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850021001053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:23:09Z","timestamp":1761819789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850021001053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1879850021001053"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2021.03.005","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Organ at Risk Dose Constraints in SABR: A Systematic Review of Active Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2021.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}